# Principal Technologies to acquire controlling stake in Syndermix AG

Principal Technologies signed a non-binding LOI to acquire a 70.7% equity interest in Syndermix AG, a Swiss medical research developer, for $44 million. The deal includes three medical technologies.

- Type: Acquisition
- Announced: 2024-12-11
- Where: Switzerland
- Value: $44.0M
- Status: announced
- Products: BioEleSonic device, Noxogen Therapeutics, TheraLect
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Principal Technologies](https://endata.com/companies/81708.md) (acquirer)
- [Syndermix AG](https://endata.com/companies/81709.md) (target)

## Sources

- [de.advfn.com](https://de.advfn.com/borse/TSXV/PTEC/nachrichten/95079648/principal-technologies-announces-acquistion-of-syn), 2024-12-11: "The Company will purchase a total 70.7% equity interest in and all loans to Syndermix from two arms-length sellers in a transaction valued at $44 million."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.